Abstract
During the course of multiple myeloma (MM), new monoclonal (M) proteins of an isotype distinct from the original clone referred to as secondary monoclonal gammopathy of undetermined significance (MGUS) have been described. We report on the frequency, characteristics, and outcome of secondary MGUS. Of the 1,942 patients with MM, 128 (6.6%) developed a secondary MGUS, at a median time of 12 months from the diagnosis of MM. The median duration of secondary MGUS was 5.9 months. Secondary MGUS was more common in patients following stem cell transplantation compared with those who had not undergone such treatment (22.7% versus 1.6%), P<0.001. Overall survival (OS) was significantly superior in MM patients who developed secondary MGUS compared with the rest of the cohort, 73 months versus 38 months respectively, P<0.001. The time of onset and duration of secondary MGUS, and failure to resolve spontaneously had an effect on OS and needs further study. . It is present in 3-4% of the general population over the age of 50 4 . The prevalence of MGUS increases with age, [5] [6] [7] [8] [9] and toxin exposure. 10 MGUS progresses to multiple myeloma (MM) or related malignancy at a rate of 1% per year. 3, 11, 12 At 25 years of follow up, the probability of progression is 11% adjusting for competing causes of mortality [13] [14] [15] . Osteoporosis, neuropathy, and thrombophlebitis have been associated with MGUS 16 .
Previous studies have found that during the course of MM, new monoclonal gammopathies of an isotype (heavy and/or light chain) distinct from the original MM can emerge. 17, 18 This entity, termed secondary MGUS 17 , has been hypothesized to be due to recapitulation of early B-cell ontogeny following stem cell transplant (SCT) 18 . Previous investigations suggest that the appearance of a secondary MGUS is associated with better outcome 19, 20 . We studied the frequency, characteristics, and natural history of secondary MGUS in MM.
Methods
We 22 .
Statistical analysis
Two-sided Fisher exact test was used to test for differences between categorical variables. Time to event analysis were done using the Kaplan-Meier method, and survival curves were compared using the two-tailed log rank test. Multivariate analysis was performed using Cox's proportional hazards model.
Results and Discussion

Frequency of secondary MGUS
We studied 1942 patients diagnosed with MM, with a median follow up of 7 years. A secondary MGUS occurred in 128 (6.6%). Secondary MGUS was more common in patients who had underwent SCT compared to those who had not undergone such a procedure; 104 of 458 patients (22.7%) versus 24 of 1484 (1.6%), respectively, P<0.001. Among patients who were followed at least 4 times over 2 years (n=439), the corresponding rates were 59 of 163 (36.2%) versus 14 of 276 (5%), respectively. Among patients who were followed at least 8 times over 2 years (n=248), the corresponding rates were 33 of 91 (36.2%) versus 12 of 157 (7.6%), respectively. with t(4;14) translocations). In 37 patients results were normal, and 26 had other cytogenetic abnormalities. In most patients (87%), the underlying MM was responsive to therapy at time of secondary MGUS diagnosis.
Survival of MM patients with a secondary MGUS
The median OS of the study cohort was 41 months. OS was significantly superior among patients who developed secondary MGUS compared to the rest of the cohort, 73 months versus 38 months respectively, P<0.001 (Figure 1) Among patients who did not undergo SCT (n=1484), OS was significantly better in those who developed a secondary MGUS (n=24) versus the rest (n=1460), 49 months versus 31 months respectively, P=0.01. The results were identical when the survival analysis was repeated after deleting patients who had achieved complete response (CR), or CR plus near CR. Among MM patients who underwent SCT (n=458), there was no significant difference in OS in those who developed a secondary MGUS (n=104) versus the rest (n=354), 73 months versus 68 months respectively, P=NS.
Median OS was significantly superior, 94 months versus 62 months (P=0.04), among patients in whom the secondary MGUS was detected more than 12 months after initial diagnosis compared with those in whom the secondary MGUS occurred sooner. Similarly, the occurrence of a secondary MGUS more than 6 months after transplant was associated with better OS, median 102 versus 68 months, P=0.02. On a Cox proportional hazards model, a longer duration of secondary MGUS was associated with significantly inferior survival, P=0.034. Similarly, among patients with secondary MGUS, there was also a trend to better OS in those in whom the MGUS resolved (n=111) compared to those with persistent MGUS (n=17), 81 months versus 48 months respectively, P=0.07.
This study shows that secondary MGUS occurs in approximately 7% of MM, and the occurrence appears several fold higher following SCT compared with patients not undergoing SCT. Since this was not a prospective study in which patients were tested at predefined regular Secondary MGUS was a favorable prognostic factor for OS, independent of year of diagnosis, age, stage, and renal function. This is consistent with findings from other studies in SCT patients 20, 23, 24 . The failure of a secondary MGUS to spontaneously resolve and the duration of secondary MGUS may affect OS, but this needs further study. 
